At JY BioMed, we believe that scientific progress is accelerated through collaboration. We actively partner with academic institutions, clinical sites, CDMOs, and CROs to develop and deliver the next generation of cell-based and exosome therapies. By aligning with world-class partners, we expand our capabilities across preclinical development, clinical research, and GMP/GTP manufacturing — laying the foundation for therapies that may one day benefit patients with difficult-to-treat conditions.

​

We seek partnerships that:

• Support advanced research in immune cell therapy, stem cells, and targeted biologics

• Provide access to GMP/GTP-compliant manufacturing for clinical-grade materials

• Enhance translational research and early-phase clinical execution

• Share a commitment to scientific excellence, regulatory integrity, and patient-centered innovation

Collaborators

Academic & Clinical Research

• Taipei Medical University: Academic collaboration supporting translational research in oncology, regenerative medicine, and immuno-oncology. TMU and its affiliated hospitals are also engaged in early-phase clinical studies.

​

CDMO (Contract Development and Manufacturing Organizations)

• Hexun Biosciences – GTP-compliant facility for clinical-grade cell therapy and exosome manufacturing

• 3D Global Biotech – CDMO for exosome bioprocessing and cell expansion technologies

• Mycenax Biotech – GMP-certified manufacturing of biologics and ADC conjugation, formulation, and fill-finish services

​

CRO (Contract Research Organizations)

• YC Biotech – Clinical regulatory CRO supporting protocol development, IRB submission, and clinical documentation for early-phase trials in Taiwan

• Pharmacology Discovery Services Taiwan (a Eurofins Discovery Partner Lab) – Preclinical CRO supporting pharmacology, toxicology, and IND-enabling studies

​

Through our partnerships, we amplify our innovation potential and remain agile in a highly competitive and regulated environment. Whether through academic exchange, joint development, or shared infrastructure, each collaboration plays a critical role in shaping the future of our pipeline.

​

We welcome future collaborations with like-minded organizations who are advancing the boundaries of science and care.​